Identification and validation of potential prognostic biomarkers in glioblastoma via the mesenchymal stem cell infiltration level

Mesenchymal stem cells (MSCs) are key components in promoting glioblastoma (GBM) progression. This study aimed to explore new therapeutic targets and related pathogenic mechanisms based on different MSCs infiltration levels in GBM patients. We estimated the relationship between cell infiltration and...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 14; p. 1406186
Main Authors Wang, Shengyu, Mao, Senlin, Li, Xiaofu, Yang, Dan, Zhou, Yinglian, Yue, Hui, Li, Bing, Li, Wei, Li, Chengyun, Zhang, Xuemei
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 02.09.2024
Subjects
glioblastoma
immune checkpoint
mesenchymal stem cell
Oncology
prognostic model
tumor microenvironment
mesenchymal stem cell
glioblastoma
tumor microenvironment
prognostic model
immune checkpoint
Online AccessGet full text

Cover

More Information
Summary:Mesenchymal stem cells (MSCs) are key components in promoting glioblastoma (GBM) progression. This study aimed to explore new therapeutic targets and related pathogenic mechanisms based on different MSCs infiltration levels in GBM patients. We estimated the relationship between cell infiltration and prognosis of GBM. Subsequently, key risk genes were identified and prognostic models were constructed by LASSO-Cox analysis. The risk genes were validated by five independent external cohorts, single-cell RNA analysis, and immunohistochemistry of human GBM tissues. TIDE analysis predicted responsiveness to immune checkpoint inhibitors in different risk groups. The MSCs infiltration level was negatively associated with survival in GBM patients. LOXL1, LOXL4, and GUCA1A are key risk genes that promote GBM progression and may act through complex intercellular communication. This research has provided a comprehensive study for exploring the MSCs infiltration environment on GBM progression, which could shed light on novel biomarkers and mechanisms involved in GBM progression.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Songyun Zhao, First Affiliated Hospital of Wenzhou Medical University, China
Edited by: Peter Hau, University Medical Center Regensburg, Germany
These authors have contributed equally to this work
Shiao-Pei Weathers, University of Texas MD Anderson Cancer Center, United States
Reviewed by: Mariana Magalhães, University of Coimbra, Portugal
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2024.1406186